ReviewJournal of neuro-oncology2004
Molecular pathogenesis of meningiomas.
Review in Journal of neuro-oncology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 82 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
82 citing papers in PubMed, 295 citations in OpenAlex.
- Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma.Journal of neuro-oncology · 2010Trial
- Obstacles and Trials in Treating Primary Brain Tumors.International journal of molecular sciences · 2026Review
- Protein expression of CD44 in patients with meningioma tumors: association with clinicopathological parameters and survival.Journal of the Egyptian National Cancer Institute · 2024Article
- A rare case of posttraumatic subdural hematoma and intratumoral hemorrhage in a left frontotemporal meningioma: a conservative approach with longitudinal follow-up. Illustrative case.Journal of neurosurgery. Case lessons · 2024Article
- Article
- Article
- Mast cells in meningiomas.European journal of histochemistry : EJH · 2024Article
- Review
- Pediatric CNS tumors and 2021 WHO classification: what do oncologists need from pathologists?Frontiers in molecular neuroscience · 2024Review
- Clinicopathological significance of concurrent ErbB receptor expression in human meningioma.Molecular and clinical oncology · 2023Article
- Intracranial mesenchymal tumor with (novel) COX14::PTEN rearrangement.Acta neuropathologica communications · 2023Article
- Radiation-Induced Meningiomas.Advances in experimental medicine and biology · 2023Article
- Integration of molecular pathology with histopathology to accurately evaluate the biological behaviour of WHO grade 2 meningiomas and patient prognosis.Journal of neuro-oncology · 2022Article
- Spinal meningiomas, from biology to management - A literature review.Frontiers in oncology · 2022Review
- The Role of MicroRNA 181d as a Possible Biomarker Associated With Tumor Progression in Meningiomas.Cureus · 2021Article
- Meningioma: A Review of Epidemiology, Pathology, Diagnosis, Treatment, and Future Directions.Biomedicines · 2021Review
- The Prognostic Value of Methylation Signatures andCancers · 2021Article
- The prognostic value of 4.1 mRNA expression in non-small cell lung cancer.Translational cancer research · 2021Article
- Comparative clinical and genomic analysis of neurofibromatosis type 2-associated cranial and spinal meningiomas.Scientific reports · 2020Article
- Metastatic meningioma: Case report of a WHO grade I meningioma with liver metastases and review of the literature.Radiology case reports · 2020Article
22 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Meningiomas are common central nervous system tumors that originate from the meningeal coverings of the brain and the spinal cord. Most meningiomas are slowly growing benign tumors that histologically correspond to World Health Organization (WHO) grade I. However, certain rare histological variants (clear cell, chordoid, papillary, and rhabdoid), as well as atypical (WHO grade II) and anaplastic (WHO grade III) meningiomas show a more aggressive biological behavior and are clinically associated with a high risk of local recurrence and a less favorable prognosis. This review summarizes the most important features of meningioma pathology and provides an up-to-date overview about the molecular mechanisms involved in meningioma initiation and progression. Current data indicate that meningioma initiation is closely linked to the inactivation of one or more members of the highly conserved protein 4.1 superfamily, including the neurofibromatosis type 2 gene product merlin/schwannomin, protein 4.IB (DAL-1) and protein 4.1R. The genetic alterations in atypical meningiomas are complex and involve losses on 1p, 6q, 10, 14q and 18q, as well as gains on multiple chromosomes. The relevant genes are still unknown. Anaplastic meningiomas show even more complex genetic alterations, including frequent alteration of the CDKN2A, p14ARF, and CDKN2B tumor suppressor genes at 9p21, as well as gene amplification on 17q23. A better understanding of the molecular mechanisms involved in meningioma pathogenesis may not only lead to the identification of novel diagnostic and prognostic marker but will also facilitate the development of new pathogenesis-based therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.